Rotigotine Medical Valley Transdermal Patch

What Is Rotigotine Medical Valley and What Is It Used For?

Rotigotine Medical Valley is a generic transdermal patch containing rotigotine, a non-ergoline dopamine agonist. It is approved for adults with moderate-to-severe Restless Legs Syndrome (RLS) and for the symptomatic treatment of Parkinson's disease – either alone in early disease or in combination with levodopa in more advanced stages.

Rotigotine is a non-ergoline dopamine agonist, meaning it mimics the action of dopamine on receptors in the brain without belonging to the ergoline class associated with rare but serious cardiac valve fibrosis. Dopamine is a neurotransmitter that plays a central role in the regulation of voluntary movement, motivation and reward processing. Both Restless Legs Syndrome and Parkinson's disease involve dysfunction of dopaminergic pathways, and dopamine agonists such as rotigotine help to restore signalling at the dopamine receptor level.

What sets the rotigotine patch apart from oral dopamine agonists such as pramipexole or ropinirole is the route of administration. Instead of being swallowed, the medication is delivered through the skin from a transdermal patch worn for 24 hours. This route avoids the gastrointestinal tract entirely, bypasses first-pass liver metabolism, and produces remarkably stable plasma concentrations of the active substance throughout the day and night. Continuous dopaminergic stimulation is thought to reduce the risk of motor fluctuations in Parkinson's disease and to provide consistent relief in RLS, where symptoms typically worsen in the evening and at night.

In Restless Legs Syndrome (RLS), Rotigotine Medical Valley is used at lower doses (1–3 mg/24h) to relieve the irresistible urge to move the legs and the unpleasant crawling, tingling or aching sensations that characterise this neurological condition. RLS is estimated to affect approximately 5–10% of adults in Western countries and is one of the most common causes of chronic insomnia. Symptoms are usually worse at rest and in the evening, and they often disrupt sleep, daytime functioning and overall quality of life.

In Parkinson's disease, the patch is used in higher doses (2–8 mg/24h as monotherapy in early disease, with the potential to increase up to 16 mg/24h when used in combination with levodopa in advanced disease). Parkinson's disease is a progressive neurodegenerative disorder caused by the loss of dopamine-producing neurons in the substantia nigra, leading to slowness of movement (bradykinesia), muscle rigidity, resting tremor and postural instability. Rotigotine helps to compensate for the dopamine deficit, reducing motor symptoms and, in advanced disease, smoothing out the "on–off" fluctuations that often complicate long-term levodopa therapy.

Rotigotine activates dopamine receptor subtypes D1 through D5, with the highest affinity for the D3 receptor. The D3 receptor is particularly enriched in limbic regions of the brain and is increasingly recognised for its role in the sensory components of Restless Legs Syndrome and in non-motor features of Parkinson's disease. By engaging multiple receptor subtypes, rotigotine offers a broad pharmacological profile compared with agents that act selectively on only one or two receptor families.

Is Rotigotine Medical Valley the Same as Neupro?

Yes. Rotigotine Medical Valley is a generic version of the originator transdermal patch, Neupro. It contains the same active substance, in the same dosage form and at the same labelled strengths, and has been approved on the basis of bioequivalence. In clinical use, the two products are interchangeable for the same indications.

When a patent expires on an originator medicinal product, generic manufacturers may apply for marketing authorisation for an equivalent version. To be approved, the generic must contain the same active substance in the same form, at the same strength, and must demonstrate bioequivalence – that is, the rate and extent of absorption of the active ingredient into the bloodstream must fall within tightly defined regulatory limits compared with the originator. Once approved, the generic is considered therapeutically equivalent and can be substituted by the prescribing physician or, in many countries, by the dispensing pharmacist.

For Rotigotine Medical Valley, the active substance, intended pharmacological effect, indications, contraindications, dosing instructions and safety profile are essentially identical to those of the originator. The differences are limited to non-active components such as adhesives, backing layers and excipients, and to commercial details such as packaging and pack sizes. Patients switching between Neupro and Rotigotine Medical Valley should not expect a change in efficacy or safety, although they may notice cosmetic differences such as patch colour or printing.

Generic equivalents play an important role in maintaining access to effective neurological therapies. They reduce the cost burden on patients and healthcare systems and increase the resilience of the supply chain by reducing dependence on a single manufacturer. For chronic conditions such as Restless Legs Syndrome and Parkinson's disease, where treatment may continue for many years, the availability of bioequivalent alternatives can be particularly valuable.

What Should You Know Before Using Rotigotine Medical Valley?

Before starting Rotigotine Medical Valley, tell your doctor about all medical conditions – particularly liver problems, cardiovascular disease, mental health disorders, eye disease and any planned imaging procedures. The patch must always be removed before MRI scans or electrical cardioversion because of its aluminium-containing backing.

Contraindications

Rotigotine Medical Valley must not be used in certain situations where the risks clearly outweigh any potential benefits. You should not use the patch if any of the following apply:

• Hypersensitivity to rotigotine or to any excipient in the patch (including sodium metabisulfite, which can cause allergic reactions in sensitive individuals)
• Magnetic resonance imaging (MRI): The patch must be removed before MRI because the aluminium-containing backing can heat in the magnetic field and cause skin burns at the application site
• Electrical cardioversion: Similarly, the patch must be removed before any electrical cardioversion procedure because of the same risk of burns from the metallic components

After removing the patch for an MRI or cardioversion, a new patch can be applied once the procedure is complete. Always inform the medical team performing the procedure that you use a rotigotine patch so that they can adjust the timing of patch removal and re-application appropriately.

Warnings and Precautions

Several important precautions should be discussed with your doctor before starting Rotigotine Medical Valley. These cover monitoring requirements and clinically significant risks that may require dose adjustment or, in some cases, choice of a different medication.

Blood pressure and orthostatic hypotension: Dopamine agonists, including rotigotine, can lower blood pressure and cause symptomatic orthostatic hypotension – a sudden drop in blood pressure on standing that may produce dizziness, lightheadedness or fainting. The risk is highest when treatment is first started, after a dose increase or in older patients. Blood pressure should be checked regularly, particularly during the first weeks of therapy.

Sudden onset of sleep: Rotigotine can cause excessive daytime sleepiness and, in some patients, episodes of falling asleep without warning during activities of daily life, including driving. These episodes can occur even after several months of stable treatment. Patients should be warned to refrain from driving or operating machinery if they experience excessive sleepiness or have had a sudden sleep episode, and should report such events to their doctor.

Eye examinations: Periodic ophthalmological examination is recommended during treatment, especially if visual symptoms develop. Any new or worsening visual disturbance between scheduled appointments should be reported promptly.

Hepatic impairment: Rotigotine has not been formally studied in patients with severe hepatic impairment, and dose adjustment may be required if liver function deteriorates during treatment. Notify your doctor of any new symptoms suggestive of liver dysfunction such as jaundice, persistent fatigue or abdominal discomfort.

Augmentation in RLS: Augmentation is a paradoxical worsening of Restless Legs Syndrome on long-term dopaminergic therapy. Symptoms may begin earlier in the day, become more intense, spread to involve the arms or trunk, or have a shorter latency at rest. Augmentation is dose-related and may necessitate a change of medication. Any worsening pattern of RLS symptoms should be reported to your doctor.

Psychiatric symptoms: Hallucinations (most often visual), confusion, paranoia, delusional thinking and aggressive behaviour have been reported in patients treated with dopamine agonists, particularly in older adults and in those with Parkinson's disease. Patients and caregivers should monitor for new psychiatric symptoms and report them to the prescribing physician.

Impulse Control Disorders

One of the most clinically significant adverse effects associated with all dopamine agonists, including rotigotine, is the development of impulse control disorders (ICDs). These behavioural changes can be devastating for patients and families, and patients themselves often do not recognise the connection to their medication. For this reason, it is essential that family members and caregivers are informed about the possibility of ICDs and know what to look for.

Impulse control disorders associated with Rotigotine Medical Valley include:

• Pathological gambling: A strong urge to gamble despite serious financial, family or personal consequences
• Hypersexuality: Significantly increased sexual desire or sexual behaviour that is out of character and causes distress to the patient or others
• Compulsive shopping or spending: An uncontrollable urge to purchase items or to spend money excessively
• Binge eating: Consuming large quantities of food in short periods, eating well beyond the point of comfort, or compulsive snacking
• Punding and dopamine dysregulation syndrome: Repetitive purposeless behaviours and a craving for higher doses of medication beyond clinical need

If any of these behaviours emerge during treatment, contact your doctor without delay. ICDs are often dose-related and may resolve with dose reduction or change of dopamine agonist. Patients with a history of impulse control problems, alcohol or drug misuse, or younger age at diagnosis may be at higher risk and should be monitored particularly carefully.

Pregnancy and Breastfeeding

Rotigotine Medical Valley should not be used during pregnancy. Animal studies have not shown direct harmful effects on pregnancy or foetal development, but human data are very limited. The potential effects of rotigotine on the developing foetus are therefore not fully known, and the patch should be avoided unless the prescribing physician judges that the potential benefit clearly outweighs the potential risk.

Breastfeeding is not recommended during treatment with Rotigotine Medical Valley. Rotigotine may pass into breast milk and could affect the nursing infant. In addition, rotigotine reduces the secretion of prolactin and may therefore inhibit lactation. Women who are pregnant, who suspect they may be pregnant, or who are planning to become pregnant should consult their doctor before continuing or initiating treatment. Women of childbearing potential should discuss effective contraception during therapy.

Children and Adolescents

Rotigotine Medical Valley is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of rotigotine in this age group have not been established for either Restless Legs Syndrome or Parkinson's disease, and there are insufficient data to support paediatric use.

Older Adults

Older patients can use Rotigotine Medical Valley, but they may be more susceptible to certain adverse effects, particularly hallucinations, confusion, orthostatic hypotension and excessive sleepiness. Cautious dose titration and close clinical monitoring are advisable. Doses should generally not be increased more rapidly than once per week, and the lowest effective dose should be used.

How Does Rotigotine Medical Valley Interact with Other Drugs?

Rotigotine Medical Valley can interact with several classes of medication, most importantly antipsychotics and dopamine antagonist anti-emetics that block dopamine receptors and reduce its effectiveness, and with sedatives, antidepressants, alcohol and antihypertensives that can amplify its central nervous system or cardiovascular effects.

Drug interactions are an important consideration in patients treated with rotigotine because many of these patients are older and may be taking multiple medications for comorbid conditions. Because rotigotine acts on dopamine receptors, agents that block dopaminergic activity can directly counteract its therapeutic effect, while drugs that share its sedative or hypotensive properties can produce additive adverse effects.

Minor Interactions and Special Considerations

In addition to the interactions listed above, several other situations require thoughtful clinical management. Patients receiving anticoagulants or antiplatelet drugs do not need dose adjustment of either medication, but should be aware that rotigotine can occasionally cause hypotension that increases the risk of falls. Patients with diabetes mellitus may experience changes in appetite or eating behaviour because of impulse control effects, and may need closer monitoring of glycaemic control.

Because rotigotine is absorbed through the skin and not via the gastrointestinal tract, it does not interact with drugs that affect gastric emptying or pH, and food and drink do not affect its absorption. However, the integrity of the patch and the condition of the skin do matter: lotions, oils, sunscreens and powders applied to the application site can interfere with adhesion and absorption. The application site should be free of these products at the time of patch placement.

What Is the Correct Dosage of Rotigotine Medical Valley?

Dosing depends on the indication. For Restless Legs Syndrome, treatment starts at 1 mg/24h and may be increased weekly by 1 mg/24h up to a maximum of 3 mg/24h. For Parkinson's disease in early stages, treatment starts at 2 mg/24h and is increased weekly by 2 mg/24h up to 8 mg/24h; in advanced disease combined with levodopa, the dose can be titrated up to 16 mg/24h. The patch is applied once daily and worn for 24 hours.

Rotigotine Medical Valley should always be initiated at the lowest dose appropriate for the indication and titrated upwards according to clinical response and tolerability. The titration schedule is designed to minimise the early adverse effects (particularly nausea, dizziness and somnolence) while allowing the patient to reach an effective maintenance dose over a few weeks. The dose should never be changed without medical advice, and changes in dosing schedule should be implemented stepwise.

Adults with Restless Legs Syndrome

Adults with Parkinson's Disease

How to Apply the Patch

Proper application of the Rotigotine Medical Valley patch is crucial for ensuring consistent drug delivery and minimising skin reactions. The patch should always be applied to clean, dry, intact skin and rotated daily. Follow these steps:

1. Choose a clean, dry skin site: Suitable areas include the shoulders, upper arms, abdomen, flanks (the sides between the ribs and hips), thighs and hips. Avoid skin folds, broken skin, irritated areas and areas with dense hair
2. Remove the previous patch first: Always take off the old patch before applying the new one to prevent overdose or duplication of dose
3. Open the sachet and peel the protective liner: Handle the patch carefully, avoiding direct contact between fingers and the adhesive, sticky surface
4. Press firmly onto the skin for 20–30 seconds: Apply the adhesive side to the chosen skin area and press the patch firmly with the palm of your hand, paying particular attention to the edges
5. Wash your hands: After handling the patch, wash your hands thoroughly with soap and water to remove any traces of the active ingredient

Missed Dose

If you forget to change the patch at the usual time, remove the old patch and apply a new one as soon as you remember, on a different skin site. If you forgot to apply a new patch after removing the old one earlier in the day, apply a new patch as soon as you remember. In all cases, apply the next patch at your usual time the following day. Do not apply two patches at once or use a higher dose to make up for a forgotten one, as this can cause a sudden increase in plasma levels and an increased risk of side effects.

Overdose

Using higher doses of Rotigotine Medical Valley than prescribed, or applying multiple patches at the same time, can lead to serious adverse effects. Symptoms of overdose may include severe nausea, vomiting, low blood pressure, hallucinations (seeing or hearing things that are not real), confusion, marked drowsiness, involuntary movements (dyskinesia) and seizures. If overdose is suspected, all patches should be removed immediately and medical attention sought. Treatment is supportive: there is no specific antidote, but the rate of decline of plasma rotigotine after patch removal is rapid and most symptoms resolve within hours.

What Are the Side Effects of Rotigotine Medical Valley?

Like all medicines, Rotigotine Medical Valley can cause side effects, although not everyone gets them. The most common are headache, nausea, drowsiness, dizziness and skin reactions at the application site. Less common but serious effects include sudden sleep onset, hallucinations, impulse control disorders and orthostatic hypotension. Frequencies are based on EMA SmPC data for the originator and confirmed for the generic.

Adverse effects with rotigotine are most common during the first weeks of treatment and after dose increases. Nausea and skin reactions at the application site are particularly typical at the start of therapy but tend to diminish as the body adjusts to continuous dopaminergic stimulation. Understanding the frequency and nature of potential side effects helps patients and their caregivers recognise when medical attention is needed and when it is reasonable to wait for early effects to settle.

Skin Reactions at the Application Site

Application site reactions are among the most common adverse effects with all rotigotine patches, including Rotigotine Medical Valley. You may experience erythema (redness), itching, mild oedema, dryness or burning sensations at the site where the patch was applied. These reactions are usually mild to moderate, resolve within a few hours of patch removal, and rarely lead to discontinuation of treatment.

To minimise the risk and severity of skin reactions:

• Rotate the application site daily and use a different area of skin each time
• Do not reuse the same skin area within 14 days
• Apply the patch only to clean, dry, intact skin free of lotions, oils, sunscreens and powders
• Avoid prolonged direct sunlight on the patch application site, as this may cause skin discolouration
• Press the patch firmly to the skin for at least 20–30 seconds after application to ensure good adhesion
• Remove the patch carefully by lifting from one corner; do not pull abruptly

If skin reactions persist for more than a few days, are severe, spread beyond the application site, or are accompanied by widespread rash or breathing difficulties, contact your doctor for advice. In some cases a generalised hypersensitivity reaction can occur and may require discontinuation of the medication.

Allergic Reactions to Sodium Metabisulfite

Rotigotine Medical Valley contains sodium metabisulfite (E223), an excipient that can rarely cause severe hypersensitivity (allergic) reactions and bronchospasm (sudden narrowing of the airways). Patients with a known sensitivity to sulfites or with asthma should be particularly careful and should report any symptoms suggestive of allergy. Contact your doctor or seek emergency medical attention immediately if you experience swelling of the face, tongue or lips, difficulty breathing, hives or a widespread rash after applying a patch.

Reporting Side Effects

Reporting suspected adverse reactions after authorisation of a medicinal product is an important way of monitoring its benefit–risk balance over time. Patients are encouraged to report any side effects through the national pharmacovigilance system in their country. In the European Union, this is typically the national medicines agency (for example, the MHRA Yellow Card scheme in the United Kingdom or the equivalent in other Member States). Reporting helps ensure that emerging safety signals can be identified and addressed promptly.

How Should You Store Rotigotine Medical Valley?

Store Rotigotine Medical Valley patches at a temperature not exceeding 30°C (86°F), in their original sachets, and out of the sight and reach of children. Used patches still contain active medication and should be folded in half with the adhesive side inward and disposed of safely.

Proper storage of Rotigotine Medical Valley patches is essential to ensure that the medication remains effective and safe throughout its shelf life. The patches are sensitive to extreme temperatures and to direct sunlight; storing them outside the recommended conditions may compromise drug delivery or accelerate degradation of the active ingredient.

• Temperature: Store at a temperature not exceeding 30°C (86°F). Do not refrigerate or freeze. Avoid exposure to direct sunlight or to heat sources such as radiators
• Packaging: Keep each patch sealed in its original sachet until you are ready to use it. Do not open sachets in advance, as this exposes the patch to air and humidity
• Children and pets: Keep all patches – both used and unused – out of the sight and reach of children and pets. Even a used patch contains a substantial amount of active rotigotine and could cause serious harm if ingested or applied to a child's skin
• Expiry date: Do not use the patch after the expiry date printed on the label and outer carton. The expiry date refers to the last day of that month
• Travel: When travelling, keep the patches in their original packaging and protect them from heat (for example, do not leave them in a hot car or in direct sun). Carry them in your hand luggage if travelling by air

Disposing of Used Patches

Used patches still contain a significant amount of active rotigotine and must be disposed of carefully to prevent accidental exposure. After removing a used patch, fold it in half with the adhesive side facing inward, place it back in its original sachet (or in a sealable plastic bag), and dispose of it safely out of the reach of children and pets.

Do not flush used patches down the toilet or place them in household waste where they could be accessible. Many countries operate medicine take-back schemes through community pharmacies; ask your pharmacist about proper disposal of unused or expired patches in your area. These precautions help protect children, pets and the environment from accidental exposure to the active substance.

What Does Rotigotine Medical Valley Contain?

The active ingredient is rotigotine. Each patch is designed to deliver a defined dose over 24 hours; the total drug content per patch exceeds the delivered dose because not all of the active ingredient is released during the 24-hour wear period. Excipients include polysiloxane adhesives, povidone, sodium metabisulfite (E223) and antioxidants such as ascorbyl palmitate (E304) and DL-α-tocopherol (E307). The backing layer contains aluminium.

Understanding the composition of Rotigotine Medical Valley is important for several reasons: it allows patients to identify potential allergens (most notably sodium metabisulfite), it explains why the patch must be removed before MRI scans (because of its aluminium-containing backing), and it helps healthcare professionals counsel patients on correct handling. The patch consists of three layers: a backing layer, a drug-containing adhesive matrix and a protective release liner that is removed before application.

Active Ingredient

• Rotigotine – available in patch strengths of 1 mg/24h, 2 mg/24h, 3 mg/24h, 4 mg/24h, 6 mg/24h and 8 mg/24h. The total drug content per patch is approximately 2.25 mg (1 mg/24h), 4.5 mg (2 mg/24h), 6.75 mg (3 mg/24h), 9 mg (4 mg/24h), 13.5 mg (6 mg/24h) and 18 mg (8 mg/24h)

Other Ingredients (Excipients)

• Poly(dimethylsiloxane, trimethylsilyl silicate) copolymer (silicone-based adhesive matrix)
• Povidone K90 (polymer that helps stabilise rotigotine in the matrix)
• Sodium metabisulfite (E223) – antioxidant; can cause allergic reactions and bronchospasm in sensitive individuals
• Ascorbyl palmitate (E304) – antioxidant
• DL-α-tocopherol (E307) – antioxidant (vitamin E derivative)

The backing layer consists of a siliconised, aluminised, colour-pigmented polyester film. The aluminium content is the reason the patch must be removed before MRI scans and electrical cardioversion. The release liner is a transparent fluoropolymer-coated polyester film that is discarded before application and that should not come into contact with the skin.

Appearance and Pack Sizes

Rotigotine Medical Valley patches are thin, square or rectangular with rounded corners, beige or skin-coloured, and printed with the dose. Each patch is sealed individually in a child-resistant sachet. They are typically supplied in cartons containing 7, 14, 28, 30, 84 or 90 patches, although not all pack sizes may be marketed in every country. Check with your pharmacist for the pack sizes available in your region.

Can You Drive While Using Rotigotine Medical Valley?

Rotigotine Medical Valley can cause significant drowsiness and unpredictable episodes of falling asleep without warning. Patients who experience these effects must not drive or operate machinery. Isolated cases of patients falling asleep while driving have been reported with rotigotine, leading to road traffic accidents.

The potential for rotigotine to cause somnolence (excessive sleepiness) and sudden sleep onset is a serious safety concern that all patients must be aware of before starting treatment. These episodes can occur without warning signs, can persist for months after starting therapy, and have led to road traffic accidents in published case series. The risk is not predictable from the dose alone and may be increased by sleep deprivation, alcohol and concomitant sedating medications.

Before driving or using any tools or machinery while using Rotigotine Medical Valley, consider the following:

• Pay close attention to how the medication affects you personally; the degree of sleepiness varies considerably between individuals
• Be especially vigilant during the first weeks of treatment, after every dose increase and during the first month after a generic substitution
• Avoid driving or operating machinery if you feel drowsy or have had any episode of suddenly falling asleep at any point during treatment
• The combination of rotigotine with alcohol, sedating medications, sleep deprivation or shift work substantially increases the risk of sudden sleep
• Discuss your driving with your doctor, who may need to inform local licensing authorities depending on your country's regulations

If you experience excessive drowsiness or sudden sleep episodes at any point during treatment, stop driving immediately and contact your doctor. Your dose may need to be reduced, an alternative medication considered, or driving discontinued until the issue is resolved.

Frequently Asked Questions About Rotigotine Medical Valley